Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockade
Our multimodal analysis of patients with metastatic NSCLC treated with ICB identified clinicopathological and immunological features associated with long-term benefits. The presence of preexisting antitumor immunity emerged as a strong predictor of long-term benefits, providing insights for potential biomarkers and therapeutic strategies for enhancing ICB outcomes in metastatic NSCLC.
Authors
- Ignacio Sánchez (ORCID: https://orcid.org/0000-0003-0086-5381)
- Álvaro Taus (ORCID: https://orcid.org/0000-0002-7331-6730)
- Miguel Galindo‐Campos (ORCID: https://orcid.org/0000-0002-0650-8660)
- Xavier Villanueva
- Albert Sánchez‐Font (ORCID: https://orcid.org/0000-0003-1026-7908)
- Edurne Arriola (ORCID: https://orcid.org/0000-0001-8960-7519)
- Max Hardy-Werbin (ORCID: https://orcid.org/0000-0001-8020-123X)
- Roberto Chalela (ORCID: https://orcid.org/0000-0003-4835-3852)
- Ignacio I. Wistuba (ORCID: https://orcid.org/0000-0003-3365-6340)
- Beatriz Sánchez‐Espiridión
- Andrew Georgiadis (ORCID: https://orcid.org/0009-0007-9121-9778)
- Ana Rovira (ORCID: https://orcid.org/0000-0003-1301-2599)
- Sharia Hernandez (ORCID: https://orcid.org/0000-0002-7746-0860)
- Pedro Rocha (ORCID: https://orcid.org/0000-0003-3221-7354)
- James R. White (ORCID: https://orcid.org/0000-0002-7535-9179)
- Laura Moliner (ORCID: https://orcid.org/0000-0002-1532-242X)
- Mario Giner
- R. Del Rey-Vergara (ORCID: https://orcid.org/0000-0002-7973-0772)
- Víctor Curull
- Beatríz Bellosillo (ORCID: https://orcid.org/0000-0002-5335-2726)
- Júlia Perera‐Bel (ORCID: https://orcid.org/0000-0002-6809-132X)
- Sergi Clavé (ORCID: https://orcid.org/0000-0002-9435-8454)
- Laura Masfarré
- Luisa M. Solis Soto (ORCID: https://orcid.org/0000-0002-1253-630X)
- Jennifer Jackson (ORCID: https://orcid.org/0000-0001-5998-1999)
- Mark Sausen (ORCID: https://orcid.org/0000-0002-2916-5269)
- N. Navarro-Gorro
- A. Rossell
- Ariadna Acedo-Terrades (ORCID: https://orcid.org/0009-0009-3222-7086)
- Albert Iñañez
- Pau Berenguer‐Molins (ORCID: https://orcid.org/0000-0002-0170-2931)
- Wei Lü (ORCID: https://orcid.org/0000-0001-6544-0208)
- Rafael Bach
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- LabCorp (United States) (US)
- Hospital Del Mar (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
Publication Details
- Journal
- OncoImmunology
- Published
- 2025-02-24
- DOI
- https://doi.org/10.1080/2162402x.2025.2469377
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- Generalitat de Catalunya
- European Society for Medical Oncology
- Sociedad Española de Oncología Médica
- Centro de Investigación Biomédica en Red de Cáncer
- University of Texas MD Anderson Cancer Center
- Instituto de Salud Carlos III